Mineralys Therapeutics (MLYS) Return on Capital Employed (2023 - 2026)
Mineralys Therapeutics (MLYS) posted Return on Capital Employed of 26.69% for Q1 2026, up 3.68% sequentially from 27.71% in Q4 2025, and up 4877.0% YoY from 0.54% in Q1 2025.
Mineralys Therapeutics (MLYS) Return on Capital Employed (2023 - 2026) Analysis & Trends
Mineralys Therapeutics has reported Return on Capital Employed for 4 years, with the latest figure at 26.69% in Q1 2026.
- Quarterly Return on Capital Employed rose 4877.0% year-over-year to 26.69% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26.69% (up 4877.0% YoY) and the FY2025 annual result came in at 40.74%, up 4911.0% from the prior year.
- Return on Capital Employed advanced to 26.69% in Q1 2026 per MLYS's latest filing, from 27.71% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 16.44% in Q2 2023 and troughed at 86.5% in Q4 2024.
- A 4-year average of 43.11% and a median of 37.5% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 5319 bps in 2024, then jumped 5879 bps in 2025.
- Over 4 years, Return on Capital Employed stood at 33.31% in 2023, then sank by 160 bps to 86.5% in 2024, then soared by 68 bps to 27.71% in 2025, then climbed by 4 bps to 26.69% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 26.69%, 27.71%, and 41.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Mineralys Therapeutics | 2.27 Bn | 1.60 Bn | - | -57.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.84% |
| Mar 31, 2026 | -26.69% |
| Dec 31, 2025 | -27.71% |
| Sep 30, 2025 | -41.43% |
| Jun 30, 2025 | -62.84% |
| Mar 31, 2025 | -75.45% |
| Dec 31, 2024 | -86.50% |
| Sep 30, 2024 | -64.24% |
| Jun 30, 2024 | -44.18% |
| Mar 31, 2024 | -37.50% |
| Dec 31, 2023 | -33.31% |
| Sep 30, 2023 | -24.72% |
| Jun 30, 2023 | -16.44% |
| Mar 31, 2023 | -19.44% |